Company: LIMN
Filing Date: 2025-01-27
Form Type: POS AM
Source: 0001104659-25-006325
Chunk: 449

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-27
Form: POS AM
Chunk 449
---
CURRING FAIR VALUE MEASUREMENTS As of September 30, 2024 and December 31, 2023, the Company’s warrant liabilities were valued at $127,562 and $376,444, respectively. Under the guidance in ASC 815-40, the warrants do not meet the criteria for equity treatment. As such, the warrants must be recorded on the condensed balance sheets at fair value. This valuation is subject to re-measurement at each balance sheet date. With each re-measurement, the warrant valuation will be adjusted to fair value, with the change in fair value recognized in the Company’s condensed statements of operations. All of the Company’s permitted investments are held in a money market fund. Fair values of these investments are determined by Level 1 inputs utilizing quoted prices (unadjusted) in active markets for identical assets. The Company’s warrant liability for the Private Placement Warrants is based on a valuation model utilizing management judgment and pricing inputs from observable and unobservable markets with less volume and transaction frequency than active markets. Significant deviations from these estimates and inputs could result in a material change in fair value. The fair value of the Private Placement Warrant liability is classified within Level 3 of the fair value hierarchy. The Company’s warrant liability for the Public Warrants is based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. The fair value of the Public Warrant liability is classified within Level 1 of the fair value hierarchy. The following table presents fair value information as of September 30, 2024 and December 31, 2023 of the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis and indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value.

| Description                             
 September 30, 2024 (Unaudited)          | ​ 
 ​ | ​ 
 ​ | Amount atFair Value 
 ​                   | ​ |         ​ | ​ | ​ 
 ​ | ​ 
 ​ | Level 1 
 ​       | ​ |         ​ | ​ | ​ 
 ​ | ​ 
 ​ | Level 2 
 ​       | ​ | ​ | ​ | ​ 
 ​ | ​ 
 ​ | Level 3 
 ​       | ​ |       ​ | ​ | ​ 
 ​ |
|:----------------------------------------|:--|:--|:--------------------|:--|----------:|:--|:--|:--|:--------|:--|----------